Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482375 · ClinicalTrials.gov registry record
Prospective Evaluation of Residual Bile Duct Stone by Peroral Cholangioscopy After Conventional ERCP
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 140
- Enrollment target
NCT03482375 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 140 participants.
The verdict
NCT03482375 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
Study Summary
Gallstone disease affects over 20 million Americans. Among patients with gallbladder disease, the prevalence of choledocholithiasis (stones in the bile duct) is estimated to be 10-20%. Endoscopic retrograde cholangiopancreatography (ERCP) is considered the standard of care for removing stones in the bile duct utilizing a variety of conventional methods including biliary sphincterotomy, sphincteroplasty, extraction balloon, retrieval basket, and mechanical lithotripsy. After removal of stones from the bile duct, an occlusion cholangiogram is usually performed to confirm complete bile duct clearance. However, cholangiogram can miss residual stones in 11- 30% of cases - especially in the setting of a dilated bile duct, large stones, severe pneumobilia, juxtapapillary diverticulum, primary sclerosing cholangitis, and after lithotripsy (mechanical, electrohydraulic, or laser). The approach to patients with choledocholithiasis requires careful attention because missed bile duct stones can cause recurrent biliary symptoms, pancreatitis, cholangitis, and has significant cost implication with the need for repeat imaging and/or procedures.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-12-17 |
| Est. Completion | 2019-02-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03482375
The ClinicalTrials.gov registry entry for NCT03482375 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03482375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03482375 about?
NCT03482375 is a clinical study titled "Prospective Evaluation of Residual Bile Duct Stone by Peroral Cholangioscopy After Conventional ERCP". Gallstone disease affects over 20 million Americans. Among patients with gallbladder disease, the prevalence of choledocholithiasis (stones in the bile duct) is estimated to be 10-20%. Endoscopic retrograde cholangiopancreatography (ERCP) is considered the standard of care for removing stones in the...
What is the current status of trial NCT03482375?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2015-12-17. Estimated completion is 2019-02-10.
Who is sponsoring clinical trial NCT03482375?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.